Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

AAV vector-mediated in vivo reprogramming into pluripotency

Open access

Abstract

In vivo reprogramming of somatic cells into induced pluripotent stem cells (iPSC) holds vast potential for basic research and regenerative medicine. However, it remains hampered by a need for vectors to express reprogramming factors (Oct-3/4, Klf4, Sox2, c-Myc; OKSM) in selected organs. Here, we report OKSM delivery vectors based on pseudotyped Adeno-associated virus (AAV). Using the AAV-DJ capsid, we could robustly reprogram mouse embryonic fibroblasts with low vector doses. Swapping to AAV8 permitted to efficiently reprogram somatic cells in adult mice by intravenous vector delivery, evidenced by hepatic or extra-hepatic teratomas and iPSC in the blood. Notably, we accomplished full in vivo reprogramming without c-Myc. Most iPSC generated in vitro or in vivo showed transcriptionally silent, intronic or intergenic vector integration, likely reflecting the increased host genome accessibility during reprogramming. Our approach crucially advances in vivo reprogramming technology, and concurrently facilitates investigations into the mechanisms and consequences of AAV persistence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-05059-x

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 In vitro reprogramming of MEF using AAV-DJ SFFV-hCO-O/K/S/M vectors. a Experimental setup. MEF were transduced at days 1 and 3 after plating with the four vectors, using a 4:1:1:1 O:K:S:M stoichiometry and one of the two indicated MOIs per experiment and per vector (with a four-fold excess of Oct-3/4). At day 5, cells were transferred from a well of a 6-well plate to a 10 cm dish. Subsequently, medium was changed every other day to iPSC medium with or without ascorbic acid (AA). First colonies with iPSC morphology were observed at day 13. The image shows a representative alkaline phosphatase staining of clone IVT-iPSC 12 at passage 1. n = 4 for MOI 1 × 104 and n = 3 for MOI 1 × 103. b Confocal images exemplifying expression of Oct-3/4, Sox2, Nanog and SSEA-1 in AAV-derived iPSC (again IVT-iPSC 12). Shown are merges of Hoechst and secondary antibody (Alexa Fluor 488-labeled) stainings. Scale bars = 20 µm. c Reverse transcription-PCR analysis to detect expression of the depicted pluripotency markers. Shown are 10 representative clones from the reprogramming series with ascorbic acid. See Supplementary Data 1 (tab “In vitro”) for details. Six of the ten shown clones (IVT-iPSC 19 to 22, 24, and 26) are positive for all markers. Hprt (Hypoxanthine-guanine phosphoribosyltransferase) served as housekeeper. C+ iPSC generated with a lentiviral vector encoding human codon-optimized OKSM (positive control); C− untreated MEF (negative control); P, passage number. d Confocal images showing expression of ectodermal, mesodermal, and endodermal markers in differentiated clone IVT-iPSC 1. Shown are merges of Hoechst and secondary antibody (Alexa Fluor 488-labeled) stainings. Scale bars = 13 µm. Confocal images in b and d were taken with a Leica SP5 microscope with a ×40 oil immersion objective and processed with ImageJ. e Hematoxylin/eosin staining of a section of a subcutaneous teratoma generated in mice via injection of clone IVT-iPSC 1. Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar = 100 µm. This figure contains elements from Servier Medical Art (http://smart.servier.com)
Fig. 1 In vitro reprogramming of MEF using AAV-DJ SFFV-hCO-O/K/S/M vectors. a Experimental setup. MEF were transduced at days 1 and 3 after plating with the four vectors, using a 4:1:1:1 O:K:S:M stoichiometry and one of the two indicated MOIs per experiment and per vector (with a four-fold excess of Oct-3/4). At day 5, cells were transferred from a well of a 6-well plate to a 10 cm dish. Subsequently, medium was changed every other day to iPSC medium with or without ascorbic acid (AA). First colonies with iPSC morphology were observed at day 13. The image shows a representative alkaline phosphatase staining of clone IVT-iPSC 12 at passage 1. n = 4 for MOI 1 × 104 and n = 3 for MOI 1 × 103. b Confocal images exemplifying expression of Oct-3/4, Sox2, Nanog and SSEA-1 in AAV-derived iPSC (again IVT-iPSC 12). Shown are merges of Hoechst and secondary antibody (Alexa Fluor 488-labeled) stainings. Scale bars = 20 µm. c Reverse transcription-PCR analysis to detect expression of the depicted pluripotency markers. Shown are 10 representative clones from the reprogramming series with ascorbic acid. See Supplementary Data 1 (tab “In vitro”) for details. Six of the ten shown clones (IVT-iPSC 19 to 22, 24, and 26) are positive for all markers. Hprt (Hypoxanthine-guanine phosphoribosyltransferase) served as housekeeper. C+ iPSC generated with a lentiviral vector encoding human codon-optimized OKSM (positive control); C− untreated MEF (negative control); P, passage number. d Confocal images showing expression of ectodermal, mesodermal, and endodermal markers in differentiated clone IVT-iPSC 1. Shown are merges of Hoechst and secondary antibody (Alexa Fluor 488-labeled) stainings. Scale bars = 13 µm. Confocal images in b and d were taken with a Leica SP5 microscope with a ×40 oil immersion objective and processed with ImageJ. e Hematoxylin/eosin staining of a section of a subcutaneous teratoma generated in mice via injection of clone IVT-iPSC 1. Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar = 100 µm. This figure contains elements from Servier Medical Art (http://smart.servier.com)CC BY · PubMed Central
Fig. 2 In vivo reprogramming in mice using scAAV8 SFFV-hCO-O/K/S/M vectors. a Experimental setup. 38 weeks-old C57BL/6 male mice were injected with 5 × 1010 (n = 9) or 2 × 1011 (n = 9) vg per vector and mouse. 2 and 4 weeks post-injection, three mice per dose and time point were sacrificed, and their organs were extracted and analyzed histopathologically. Remaining mice were sacrificed upon appearance of palpable teratomas (week [w] 7, 8 and 10: 2 × 1011 vg group; month [m] 9: 5 × 1010 vg group). b Hematoxylin/eosin staining of liver teratoma section (mouse treated with 2 × 1011 vg and sacrificed at week 8 post-injection). Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar = 100 µm. c iPSC clone derived from a teratoma formed in the liver of the mouse from panel a. Scale bar = 100 µm. The shown clone is representative of 14 IVV-iPSC clones that were derived from mice treated with the OKSM cocktail (four more [IVV-iPSC 15 to 18] were later obtained with OKS, Supplementary Data 1), six of which were from teratomas (see also Fig. 3b). d Hematoxylin/eosin staining of a section of a subcutaneous teratoma generated in mice via injection of clone IVV-iPSC 9. Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar = 100 µm. e In vivo reprogramming experiment using a high vector dose (1 × 1012 vg per vector and mouse) injected into 15 weeks-old C57BL/6 male mice (n = 3). Mice were sacrificed upon appearance of palpable teratomas at week 6 post-injection. f Repeat of experiment from panel e, using a scAAV8 vector encoding GFP instead of c-Myc (n = 3). All three mice were sacrificed at month 12 post-injection. One mouse (Supplementary Table 5, mouse #1, assay #6) had a teratoma (yellow arrowhead) in the pancreas. g Histological sections of teratomas (extracted 8 weeks post-injection) from mice injected with a cocktail of scAAV8 vectors encoding hCO-O/K/S/M or TTR promoter-driven Cre recombinase (n = 3). Sections were stained with hematoxylin/eosin and an anti-β-galactosidase (left) or anti-Oct-3/4 antibody (right). Scale bars = 200 µm. This figure contains elements from Servier Medical Art (http://smart.servier.com)
Fig. 2 In vivo reprogramming in mice using scAAV8 SFFV-hCO-O/K/S/M vectors. a Experimental setup. 38 weeks-old C57BL/6 male mice were injected with 5 × 1010 (n = 9) or 2 × 1011 (n = 9) vg per vector and mouse. 2 and 4 weeks post-injection, three mice per dose and time point were sacrificed, and their organs were extracted and analyzed histopathologically. Remaining mice were sacrificed upon appearance of palpable teratomas (week [w] 7, 8 and 10: 2 × 1011 vg group; month [m] 9: 5 × 1010 vg group). b Hematoxylin/eosin staining of liver teratoma section (mouse treated with 2 × 1011 vg and sacrificed at week 8 post-injection). Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar = 100 µm. c iPSC clone derived from a teratoma formed in the liver of the mouse from panel a. Scale bar = 100 µm. The shown clone is representative of 14 IVV-iPSC clones that were derived from mice treated with the OKSM cocktail (four more [IVV-iPSC 15 to 18] were later obtained with OKS, Supplementary Data 1), six of which were from teratomas (see also Fig. 3b). d Hematoxylin/eosin staining of a section of a subcutaneous teratoma generated in mice via injection of clone IVV-iPSC 9. Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar = 100 µm. e In vivo reprogramming experiment using a high vector dose (1 × 1012 vg per vector and mouse) injected into 15 weeks-old C57BL/6 male mice (n = 3). Mice were sacrificed upon appearance of palpable teratomas at week 6 post-injection. f Repeat of experiment from panel e, using a scAAV8 vector encoding GFP instead of c-Myc (n = 3). All three mice were sacrificed at month 12 post-injection. One mouse (Supplementary Table 5, mouse #1, assay #6) had a teratoma (yellow arrowhead) in the pancreas. g Histological sections of teratomas (extracted 8 weeks post-injection) from mice injected with a cocktail of scAAV8 vectors encoding hCO-O/K/S/M or TTR promoter-driven Cre recombinase (n = 3). Sections were stained with hematoxylin/eosin and an anti-β-galactosidase (left) or anti-Oct-3/4 antibody (right). Scale bars = 200 µm. This figure contains elements from Servier Medical Art (http://smart.servier.com)CC BY · PubMed Central
Fig. 3 Expression of the four reprogramming factors and evidence for reprogramming in mouse liver. a Detection of AAV-encoded hCO-Oct-3/4 (brown staining) via immunohistochemistry in liver sections obtained from mice 2 or 4 weeks post-injection with 5 × 1010 (low dose) or 2 × 1011 (high dose) vg per vector and mouse (n = 3 per dose and time point). Symbols are the same as in b. Nuclei were counterstained with hematoxylin. Scale bar = 100 µm. b Quantification of the expression of AAV-encoded hCO-Oct-3/4, -Klf4, -Sox2 and -c-Myc by qRT-PCR. A delta Ct analysis was used in which the values were normalized to the expression of a housekeeper gene (actin) and then expressed as fold-changes over the values (set to 1) for the low dose at 2 weeks for each reprogramming factor. Each point represents a single mouse. Center values are means and error bars are S.D. Statistical analyses were performed by one-way ANOVA with Tukey’s Multiple Comparison Test. *, p < 0.05; **, p < 0.01. c, d Evidence for reprogramming in livers of AAV-OKSM-treated mice (2 × 1011 vg, sacrificed 8 weeks after administration) obtained via immunohistochemical detection of expression of Tfe3 (c), a marker for pluripotency, and PCNA (d), a marker for proliferation. Note the largely overlapping patches of Tfe3- and PCNA-positive cells in the serial sections from the same liver of an AAV-OKSM-treated mouse in the rightmost panels. Scale bars in the left and central panels = 100 µm, and in the right panels = 500 µm
Fig. 3 Expression of the four reprogramming factors and evidence for reprogramming in mouse liver. a Detection of AAV-encoded hCO-Oct-3/4 (brown staining) via immunohistochemistry in liver sections obtained from mice 2 or 4 weeks post-injection with 5 × 1010 (low dose) or 2 × 1011 (high dose) vg per vector and mouse (n = 3 per dose and time point). Symbols are the same as in b. Nuclei were counterstained with hematoxylin. Scale bar = 100 µm. b Quantification of the expression of AAV-encoded hCO-Oct-3/4, -Klf4, -Sox2 and -c-Myc by qRT-PCR. A delta Ct analysis was used in which the values were normalized to the expression of a housekeeper gene (actin) and then expressed as fold-changes over the values (set to 1) for the low dose at 2 weeks for each reprogramming factor. Each point represents a single mouse. Center values are means and error bars are S.D. Statistical analyses were performed by one-way ANOVA with Tukey’s Multiple Comparison Test. *, p < 0.05; **, p < 0.01. c, d Evidence for reprogramming in livers of AAV-OKSM-treated mice (2 × 1011 vg, sacrificed 8 weeks after administration) obtained via immunohistochemical detection of expression of Tfe3 (c), a marker for pluripotency, and PCNA (d), a marker for proliferation. Note the largely overlapping patches of Tfe3- and PCNA-positive cells in the serial sections from the same liver of an AAV-OKSM-treated mouse in the rightmost panels. Scale bars in the left and central panels = 100 µm, and in the right panels = 500 µmCC BY · PubMed Central
Fig. 4 Analysis of AAV vector traces and integration sites in scAAV/OKSM-derived cellular clones. a PCR analysis of 19 clones generated in vitro and analyzed at an early passage (between passage 0 and 6). Top gel: PCR with primers amplifying the whole cassette, from SFFV promoter to polyadenylation signal. Three or four distinct bands are detected, which correspond to the four AAV reprogramming vectors used. Bottom gel: PCR to detect the Hprt housekeeper (HK) gene. LVV, iPSC cells generated with a lentiviral vector encoding human codon-optimized OKSM; MEF, untreated MEF; H2O, control PCR using water instead of DNA template. Sizes of a DNA marker are shown in kilobases (kb) on the left. The asterisks highlight IVT-iPSC clones which may not have been fully reprogrammed (Supplementary Data 1). b PCR analysis of 14 AAV-iPSC clones generated in vivo using a MOI of 2 × 1011 and analyzed at an early passage (between passage 2 and 4). See panel a for details as well as Supplementary Data 1 for information on all clones. c Graph showing the number of AAV insertion sites (IS) identified by nrLAM-PCR or TES in the cellular clones shown in a (blue bars, generated in vitro) and b (green bars, generated in vivo). d PhenoGram plot (generated with the tool http://visualization.ritchielab.psu.edu/phenograms/plot) depicting the distribution of AAV IS across all mouse chromosomes, segregated into cellular clones generated in vitro (blue) or in vivo (green) (same color scheme as in c). e Pie chart illustrating the proportions of AAV vector integrations (total n = 180) in exons, introns or intergenic regions. Of the 10 hits in exons, two affected cancer-associated (CA) genes based on the Genecards (GC) database, or seven based on the Candidate Cancer Gene Database (CCGD) (see Supplementary Data 2 for details)
Fig. 4 Analysis of AAV vector traces and integration sites in scAAV/OKSM-derived cellular clones. a PCR analysis of 19 clones generated in vitro and analyzed at an early passage (between passage 0 and 6). Top gel: PCR with primers amplifying the whole cassette, from SFFV promoter to polyadenylation signal. Three or four distinct bands are detected, which correspond to the four AAV reprogramming vectors used. Bottom gel: PCR to detect the Hprt housekeeper (HK) gene. LVV, iPSC cells generated with a lentiviral vector encoding human codon-optimized OKSM; MEF, untreated MEF; H2O, control PCR using water instead of DNA template. Sizes of a DNA marker are shown in kilobases (kb) on the left. The asterisks highlight IVT-iPSC clones which may not have been fully reprogrammed (Supplementary Data 1). b PCR analysis of 14 AAV-iPSC clones generated in vivo using a MOI of 2 × 1011 and analyzed at an early passage (between passage 2 and 4). See panel a for details as well as Supplementary Data 1 for information on all clones. c Graph showing the number of AAV insertion sites (IS) identified by nrLAM-PCR or TES in the cellular clones shown in a (blue bars, generated in vitro) and b (green bars, generated in vivo). d PhenoGram plot (generated with the tool http://visualization.ritchielab.psu.edu/phenograms/plot) depicting the distribution of AAV IS across all mouse chromosomes, segregated into cellular clones generated in vitro (blue) or in vivo (green) (same color scheme as in c). e Pie chart illustrating the proportions of AAV vector integrations (total n = 180) in exons, introns or intergenic regions. Of the 10 hits in exons, two affected cancer-associated (CA) genes based on the Genecards (GC) database, or seven based on the Candidate Cancer Gene Database (CCGD) (see Supplementary Data 2 for details)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 65

Metadata

Authors
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., Schmidt, M., Serrano, M., & Grimm, D.
Affiliations
  • Heidelberg University (DE)
  • Spanish National Cancer Research Centre (ES)
  • German Cancer Research Center (DE)
  • Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author
  • Serrano, Manuel
  • Grimm, Dirk
Venue
Nature Communications
Published
2018-07-09
Volume
9
Issue
1
Pages
2651-2651
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2809896540
Cited by
64
References
81
Citations by year
2026: 6 · 2025: 8 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 8 · 2019: 3 · 2018: 1
FWCI
1.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Deutsche Forschungsgemeinschaft (SFB1129-TP2, TRR179-TP18, EXC81)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
in vivo reprogramming, induced pluripotent stem cells, adeno-associated virus vectors, AAV8, mouse embryonic fibroblasts, teratoma, vector integration, genome accessibility
MeSH terms
Kruppel-Like Factor 4, Dependovirus, Animals, Cell Line, Cells, Cultured, Embryo, Mammalian, Fibroblasts, Genetic Vectors, Humans, Mice, Inbred C57BL, Mice, Nude, Transcription Factors, Transduction, Genetic, Gene Expression, Sequence Analysis, DNA, Induced Pluripotent Stem Cells, HEK293 Cells, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV vector-mediated in vivo reprogramming into pluripotency. https://app.cochat.ai/papers/10.1038/s41467-018-05059-x
The paper
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., Schmidt, M., Serrano, M., & Grimm, D. (2018). AAV vector-mediated in vivo reprogramming into pluripotency. Nature Communications. https://doi.org/10.1038/s41467-018-05059-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.